Fate Therapeutics to Present at Upcoming March Investor Conferences

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE), a biopharmaceutical firm focused on cellular immunotherapies for cancer, announced its participation in three upcoming investor conferences. These include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 11:10 AM ET, the Barclays Global Healthcare Conference on March 16, 2022, at 11:45 AM ET, and the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. Each presentation will be available on-demand, with recordings accessible via the Company's website shortly after the events.

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

• Cowen 42^nd Annual Health Care Conference available on demand on Wednesday, March 9, 2022 at 11:10 AM ET
• Barclays Global Healthcare Conference available on demand on Wednesday, March 16, 2022 at 11:45 AM ET
• Oppenheimer 32^nd Annual Healthcare Conference available on demand on Thursday, March 17, 2022 at 8:00 AM ET
  

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

What are the dates for Fate Therapeutics' upcoming investor conferences?

Fate Therapeutics will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 11:10 AM ET, Barclays Global Healthcare Conference on March 16, 2022, at 11:45 AM ET, and Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET.

Where can I watch Fate Therapeutics' conference presentations?

You can access the live webcasts of Fate Therapeutics' presentations in the 'Events & Presentations' section of their website shortly after each event.

What is the main focus of Fate Therapeutics?

Fate Therapeutics is dedicated to developing innovative cellular immunotherapies specifically targeting cancer using its proprietary induced pluripotent stem cell (iPSC) platform.

What types of products does Fate Therapeutics specialize in?

The company specializes in off-the-shelf, iPSC-derived natural killer (NK) and T-cell products aimed at enhancing established cancer therapies.

What is the stock symbol for Fate Therapeutics?

The stock symbol for Fate Therapeutics is FATE, and it is traded on NASDAQ.